These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 7776074)

  • 1. Comparative safety and efficacy of two immune globulin products in Kawasaki disease.
    Rosenfeld EA; Shulman ST; Corydon KE; Mason W; Takahashi M; Kuroda C
    J Pediatr; 1995 Jun; 126(6):1000-3. PubMed ID: 7776074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independent of salicylate dose.
    Terai M; Shulman ST
    J Pediatr; 1997 Dec; 131(6):888-93. PubMed ID: 9427895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pentoxifylline and intravenous gamma globulin combination therapy for acute Kawasaki disease.
    Furukawa S; Matsubara T; Umezawa Y; Motohashi T; Ino T; Yabuta K
    Eur J Pediatr; 1994 Sep; 153(9):663-7. PubMed ID: 7957426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of plasmin-treated intravenous gamma-globulin for therapy of Kawasaki syndrome.
    Hsu CH; Chen MR; Hwang FY; Kao HA; Hung HY; Hsu CH
    Pediatr Infect Dis J; 1993 Jun; 12(6):509-12. PubMed ID: 8345983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of coronary artery lesions after intravenous gamma-globulin treatment in Kawasaki disease.
    Mori M; Imagawa T; Yasui K; Kanaya A; Yokota S
    J Pediatr; 2000 Aug; 137(2):177-80. PubMed ID: 10931408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kawasaki disease in infants less than one year of age.
    Rosenfeld EA; Corydon KE; Shulman ST
    J Pediatr; 1995 Apr; 126(4):524-9. PubMed ID: 7699529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical manifestations and effects of IVGG in patients with Kawasaki disease].
    Hwang KP; Wu JR; Huang LY; Liou CC; Huang TY
    Kaohsiung J Med Sci; 1996 Mar; 12(3):159-66. PubMed ID: 8709183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective high dose gamma-globulin treatment in Kawasaki disease: assessment of clinical aspects and cost effectiveness.
    Sato N; Sugimura T; Akagi T; Yamakawa R; Hashino K; Eto G; Iemura M; Ishii M; Kato H
    Pediatr Int; 1999 Feb; 41(1):1-7. PubMed ID: 10200128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Iv gamma globulin treatment of Kawasaki disease in Japan: results of a nationwide survey.
    Yanagawa H; Yashiro M; Nakamura Y; Sakata K; Kawasaki T
    Acta Paediatr; 1995 Jul; 84(7):765-8. PubMed ID: 7549294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gamma globulin re-treatment in Kawasaki disease.
    Sundel RP; Burns JC; Baker A; Beiser AS; Newburger JW
    J Pediatr; 1993 Oct; 123(4):657-9. PubMed ID: 8410524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous gamma-globulin for Kawasaki disease.
    Furusho K; Kamiya T; Nakano H; Kiyosawa N; Shinomiya K; Hayashidera T; Tamura T; Hirose O; Manabe Y; Yokoyama T
    Acta Paediatr Jpn; 1991 Dec; 33(6):799-804. PubMed ID: 1801560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of intravenous gamma-globulin for Kawasaki disease: effects on cardiac sequelae.
    Yanagawa H; Nakamura Y; Sakata K; Yashiro M
    Pediatr Cardiol; 1997; 18(1):19-23. PubMed ID: 8960487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of Kawasaki disease in the British Isles.
    Dhillon R; Newton L; Rudd PT; Hall SM
    Arch Dis Child; 1993 Dec; 69(6):631-6; discussion 637-8. PubMed ID: 8285773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patients diagnosed with Kawasaki disease before the fifth day of illness have a higher risk of coronary artery aneurysm.
    Nomura Y; Masuda K; Yoshinaga M; Sameshima K; Miyata K
    Pediatr Int; 2002 Aug; 44(4):353-7. PubMed ID: 12139556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Study on coronary artery lesions in patients with Kawasaki disease: recent 9 years' experience].
    Wu JR; Hwang KP; Tu JG; Dai ZK; Huang TY
    Gaoxiong Yi Xue Ke Xue Za Zhi; 1993 Jan; 9(1):27-38. PubMed ID: 7682261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive risk factors for coronary artery abnormalities in Kawasaki disease.
    Kim T; Choi W; Woo CW; Choi B; Lee J; Lee K; Son C; Lee J
    Eur J Pediatr; 2007 May; 166(5):421-5. PubMed ID: 17033807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose intravenous gammaglobulin for Kawasaki disease.
    Furusho K; Kamiya T; Nakano H; Kiyosawa N; Shinomiya K; Hayashidera T; Tamura T; Hirose O; Manabe Y; Yokoyama T
    Lancet; 1984 Nov; 2(8411):1055-8. PubMed ID: 6209513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coronary risk factors in Kawasaki disease treated with additional gammaglobulin.
    Miura M; Ohki H; Tsuchihashi T; Yamagishi H; Katada Y; Yamada K; Yamashita Y; Sugaya A; Komiyama O; Shiro H
    Arch Dis Child; 2004 Aug; 89(8):776-80. PubMed ID: 15269082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinical efficacy of IVGG in Kawasaki disease.
    Rowley AH; Shulman ST
    Clin Rev Allergy; 1992; 10(1-2):81-91. PubMed ID: 1606526
    [No Abstract]   [Full Text] [Related]  

  • 20. Immune hemolysis, disseminated intravascular coagulation, and serum sickness after large doses of immune globulin given intravenously for Kawasaki disease.
    Comenzo RL; Malachowski ME; Meissner HC; Fulton DR; Berkman EM
    J Pediatr; 1992 Jun; 120(6):926-8. PubMed ID: 1593353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.